PATENT CLAIM ANALYSIS

Application Number: 15891626
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "183000"]

Abstract:
The present invention relates to the treatment of acquired and genetic heart conditions in a subject by the inhibition of SGK1, including Long QT syndrome and cardiovascular disease, including dilated cardiomyopathy. Cardiovascular diseases treatable by SGK1 inhibition include heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure. The present invention also identifies selective inhibitors of SGK1. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of SG.

Claim (Index 23):
The method of  claim 20 , wherein the dilated cardiomyopathy is characterized by a mutation in the MYH7 gene.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 88.0
- Lexical Diversity: 1.64912
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15024943', '14106206', '12435347', '11983987', '10491323']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7592212355155054
- 35 USC 102 Novelty (BERT): 0.5662418865999981
- Combined Prediction Score: 0.7399233006239547
- Mean Citation Score: 256.81156200000004
- Max Citation Score: 584.2065
- Similarity Product: 305.5920934599638

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test